Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam and Collaborators Present New Clinical Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Business Wire April 28, 2014

Alnylam's McSwiggen Patent Upheld in European Opposition Proceedings

Business Wire April 7, 2014

Alnylam to Webcast Presentation at 13th Annual Needham Healthcare Conference

Business Wire April 2, 2014

Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)

Business Wire April 2, 2014

Genzyme Exercises its Right to Purchase Additional Shares of Alnylam Common Stock

Business Wire March 26, 2014

Apply Market Savvy to Bear Market Debris; Uncover Biotech Treasures: Cleland and Ireland

Equities.com March 24, 2014

Alnylam to Present Data from its RNAi Therapeutic Programs Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) at XIVth International Symposium on Amyloidosis (ISA)

Business Wire March 21, 2014

Alnylam to Webcast Presentation at Barclays Global Healthcare Conference

Business Wire March 6, 2014

Alnylam Announces Closing of Previously Announced Acquisition of Merck's Sirna Therapeutics Subsidiary

Business Wire March 6, 2014

Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines

Business Wire February 27, 2014

Alnylam to Webcast Presentation at Cowen and Company 34th Annual Health Care Conference

Business Wire February 25, 2014

ETF Profile: iShares Russell 2000 Index ETF

Equities.com February 25, 2014

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities

Business Wire February 13, 2014

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results

Business Wire February 6, 2014

Ambrx Appoints Barry Greene to Board of Directors

PR Newswire February 5, 2014

Over 25 Companies to Present at Emerald Groundhog Investment Forum: Thursday, February 6th

Business Wire February 4, 2014

Alnylam to Webcast Presentation at Upcoming Investor Conferences

Business Wire February 4, 2014

Investment Industry to Gather in Philadelphia at 21st Annual Groundhog Investment Forum

Business Wire January 30, 2014

RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics

Accesswire January 24, 2014

Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

Business Wire January 22, 2014